查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1857525

支氣管擴張治療市場：2025-2032年全球預測（按藥物類型、給藥途徑、病患族群、支氣管擴張類型及分銷管道分類）

Bronchiectasis Drugs Market by Drug Type, Route Of Administration, Patient Demographics, Bronchiectasis Type, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，支氣管擴張藥物市場將成長至 31.3 億美元，複合年成長率為 9.46%。

關鍵市場統計數據
基準年 2024 15.2億美元
預計年份：2025年 16.5億美元
預測年份 2032 31.3億美元
複合年成長率 (%) 9.46%

本書對支氣管擴張藥物治療的發展、臨床重點以及不斷演變的治療創新框架進行了簡明扼要且權威的說明。

由於診斷意識的提高、治療假設的拓展以及對生活品質日益重視，支氣管擴張症已從臨床上的默默無聞轉變為藥物研發的重點。近年來，抗發炎策略、標靶抗菌療法、氣道清除方法以及症狀性支氣管擴張症的研究，與影像學、痰液微生物學和縱向患者登記技術的進步相融合。臨床見解與轉化科學的這種融合，使臨床醫生和相關人員能夠將氣喘視為一種可治療的慢性疾病，而非一種不可避免的進行性疾病。

因此，目前研發管線涵蓋了現有藥物的再利用、新型化合物以及旨在解決支氣管擴張多因子病理生理機制的遞送最佳化製劑。患者報告結局和減少急性加重次數正日益成為監管對話中的關鍵終點，而支付方和醫療服務提供方則關注那些能夠顯著降低醫療資源利用率並改善患者日常生活功能的治療方法。因此，策略決策需要綜合考慮臨床證據、治療差異化以及實際實施障礙，才能將科學進步轉化為永續的患者獲益。

深入說明標靶免疫調節、個人化治療和給藥創新如何重塑支氣管擴張的治療模式

支氣管擴張的治療方法正在經歷深刻的變革，這主要得益於靶向免疫調節、精準抗生素管理和吸入給藥系統等領​​域的創新。首先，超越廣泛使用皮質類固醇的抗發炎策略的出現，包括選擇性通路調節劑和輔助藥物，重塑了治療模式，使其優先控制慢性炎症，同時避免不可接受的全身暴露。這種轉變，加上對氣道微生物組動態變化更深入的理解，正在推動旨在降低病原體負荷並維持微生物生態系統的抗生素和生物製藥的研發。

同時，器械和製劑主導的進步，例如吸入製劑和最佳化的霧化器技術，提高了局部藥物濃度和耐受性，從而減少了長期治療的阻力。在監管和循證方面，相關人員目前優先考慮以患者為中心的終點指標，例如病情加重頻率、功能能力和健康相關的生活品質，這正在影響臨床試驗設計和上市後價值論證。總而言之，這些轉變正在推動支氣管擴張症管理朝著以患者為中心、精準化的方向發展，使臨床目標與產品創新和推廣路徑保持一致。

本文從實際角度探討了美國近期關稅政策變化如何影響呼吸系統治療藥物供應鏈的韌性、採購調整和籌資策略轉變。

美國近期關稅政策的變化為呼吸系統藥物的跨境供應鏈和採購規劃帶來了新的變數。關稅對不同產品類別和原料的適用程度不一，可能會影響活性藥物原料藥、輔料、製劑和專用給藥裝置的採購決策。事實上，製造商和經銷商正在重新評估供應商多元化、合約條款和到岸成本模型，以確保供應的連續性和可預測的商業條款。

為應對關稅帶來的成本壓力，一些行業相關人員正在加快生產能力的本地化，簽訂包含對沖條款的長期供應契約，或最佳化產品系列，優先選擇受關稅上漲影響較小的配方和包裝形式。同時，採購者和醫療系統正在調整競標結構和庫存策略，以減輕短期價格波動的影響。供應鏈的透明度、替代採購管道以及與物流合作夥伴的協作規劃，有助於確保病患在關稅帶來的不利影響下仍能獲得醫療服務和保障醫療服務的連續性。

一個將治療層級、給藥途徑、患者群體、疾病模式和分銷管道與策略決策聯繫起來的綜合細分框架

透過精細的細分視角，將藥物屬性、患者需求和通路結合，從而明確支氣管擴張治療整體情況的治療和商業策略。依藥物類型分類，抗發炎藥物（包括皮質類固醇和非類固醇抗發炎藥物）主要針對慢性發炎環境，而抗生素則著重於抑制病原體和控制感染。支氣管擴張劑依其作用機轉分為長效和短效兩種，以滿足維持治療和搶救治療的需求，而黏液溶解劑則針對痰液黏度和清除機制。這種藥理學分類有助於產品定位、處方討論和組合方案。

給藥途徑決定了病人的依從性和用藥方案。吸入療法可最大限度地減少全身暴露，並支持居家治療；而注射療法（包括靜脈注射和皮下注射）則用於病情嚴重加重或使用生物製藥時。口服療法因其使用方便和便於門診管理，仍然是首選。患者的人口統計學特徵進一步影響臨床策略，因為成人、老年和兒童患者群體在併發症、耐受性指標和劑量需求方面存在差異。支氣管擴張的分類有助於診斷和預後，進而影響治療方法的選擇和臨床試驗隊列的篩選。最後，分銷管道的細分——醫院、線上和零售——決定了病患的就醫途徑、報銷流程和病患援助計畫的設計。

從策略區域視角探討醫療保健系統、監管框架和醫療服務體系如何影響全球市場支氣管擴張治療的可近性和應用。

地理因素影響支氣管擴張藥物的臨床應用、監管預期和商業化策略。美洲的醫療保健系統融合了以醫院為主導的加護治療和不斷擴展的門診服務，並高度重視真實世界證據的產生和多方相關人員的報銷機制。該地區的臨床網路和患者登記系統支援長期療效追蹤和可操作性研究，為報銷文件和指南制定提供依據。

在歐洲、中東和非洲，監管協調工作和不同的報銷環境要求臨床敘述具有適應性，並需提供區域性的衛生經濟學論點。在某些地區，呼吸系統藥物（存在大量未滿足的需求）的加速核准途徑與嚴格的成本效益評估並存，這就需要量身定做的證據材料。在亞太地區，醫療基礎設施的異質性、吸入技術的快速普及以及對本地生產能力的持續投入，都推動了獨特的商業化策略。總而言之，這些區域差異凸顯了靈活的市場推廣計畫和證據產生策略的重要性，這些計畫和策略應反映區域支付方的優先事項和臨床實踐模式。

對支氣管擴張治療生態系中主要企業的競爭定位、創新路徑和合作模式進行深入分析

支氣管擴張治療領域的競爭格局呈現出多元化的態勢，既有經驗豐富的肺科專家，也有專注於該領域的生物技術公司和大型多元化製藥公司。領先企業通常透過專有的遞送平台、生物製劑方法和抗菌藥物管理策略來降低抗藥性風險，從而實現差異化競爭。其他企業則專注於漸進式創新，例如將已知的活性分子改良為吸入劑或長效製劑，以提高耐受性和患者依從性；還有一些企業致力於研發First-in-Class靶點，以調節參與粘液分泌過多和氣道重塑的特定炎症通路。

合作研究的重要性日益凸顯，因為臨床開發通常需要獲得專門的註冊、診斷能力和病患支援服務。研發人員與受託製造廠商之間的夥伴關係能夠實現靈活的規模化生產和局部生產，而許可協議則被用於加速地域擴張。從商業性角度來看，那些將強大的臨床差異化優勢與完善的患者支持和醫療專業人員教育計畫相結合的市場參與企業，更有可能獲得處方權和臨床應用。此外，投資於核准後證據產生和數位化依從性解決方案的機構，往往能夠增強其長期價值提案。

為領導團隊提供切實可行、影響深遠的建議，以促進臨床應用，增強韌性，並在支氣管擴張治療中為患者帶來可衡量的益處。

對於尋求持續差異化優勢和提升患者療效的行業領導者而言，一系列切實可行的措施可以加速臨床應用和商業性成功：首先，投資於評估病情加重負擔、功能性結局和醫療資源利用情況的臨床試驗和真實世界試驗，並以可靠的患者報告指標補充臨床終點。其次，最佳化給藥途徑以減輕治療負擔。吸入式和易於使用的製劑能夠減少全身暴露，符合臨床醫師的偏好和病患的遵從性。

接下來，透過供應商多元化、區域製造夥伴關係以及降低關稅和物流中斷風險的庫存策略，增強供應鏈韌性。此外，設計整合醫院、零售和線上藥局通路的通路和病患支援路徑，最大限度地提高醫療服務的可近性和連續性。最後，投入資源，調動包括臨床專家、支付方證據團隊和病患權益計劃團體在內的跨職能相關人員，共同建構一致的價值主張，推動其融入治療方案和流程。採取這些協作措施，能夠提高治療方法創新轉化為更好療效和持續臨床應用的可能性。

對混合方法研究方法的清晰描述，該方法結合了臨床證據審查、監管分析、相關人員訪談和產品生命週期評估。

本研究採用混合方法，結合了臨床文獻評估、監管環境審查、相關人員訪談以及器材和製劑趨勢分析。臨床文獻評估重點在於研究設計要素、終點選擇以及各治療層級的安全性概況。監管指南和公告的審查旨在識別不斷變化的核准標準和上市後證據預期。來自臨床醫生、藥品目錄管理人員和供應鏈專家的主要定性意見有助於解讀推廣應用障礙和營運限制。

為了補充定性分析，產品和技術評估專注於交付系統、生產依賴性以及低溫運輸或處理要求。採用交叉檢驗技術來協調不同的資料點，確保結論的一致性。在適用情況下，也考慮了區域監管和報銷的影響，以完善戰略意義。這種混合方法為所提出的見解和建議奠定了堅實的基礎，強調了其對臨床開發、商業化和營運團隊的實際應用價值。

總結全文強調，需要整合臨床、營運和商業策略，才能在支氣管擴張治療中實現治療價值。

要維持支氣管擴張藥物研發的持續勢頭，需要製定整合策略，將科學創新、營運韌性和相關人員合作相結合；而商業性成功則取決於靈活的分銷模式、引人入勝的醫保方案以及以患者為中心的療效方面的顯著改善。同樣重要的是，要能夠透過積極的規劃和夥伴關係來應對供應鏈波動、監管差異和不斷變化的臨床預期。

最終，最有效的方案將治療設計與實際應用相結合，並將臨床療效與有助於證明依從性、可近性和長期價值的機制相結合。那些秉持這種整體觀點——投資於有針對性的循證實踐、穩健的營運和持續的相關人員參與——的機構，最能將科學進步轉化為患者照護和醫療系統績效方面的切實改進。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 吸入脂質體抗生素治療支氣管擴張的療效和安全性結果
  • 利用CFTR調變器治療非囊腫纖維化支氣管擴張症
  • 針對支氣管擴張症嗜中性白血球發炎路徑的單株抗體治療方法的研發
  • 新型低分子量生物膜分散劑可增強支氣管擴張患者的抗生素活性
  • 將基於生物標記的患者分層模型應用於支氣管擴張症的個人化治療
  • 真實世界臨床試驗對支氣管擴張症長期療效及健保報銷的影響
  • 監管獎勵和孤兒藥認定可加速新型支氣管擴張藥物的核准
  • 抗微生物抗藥性和抗菌藥物管理在設計下一代支氣管擴張藥物的挑戰

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 支氣管擴張藥物市場（依藥物類型分類）

  • 抗發炎藥
    • 皮質類固醇
    • 非類固醇消炎劑
  • 抗生素
  • 支氣管擴張劑
    • 長效支氣管擴張劑
    • 短效支氣管擴張劑
  • 祛痰藥

9. 支氣管擴張藥物市場（依給藥途徑分類）

  • 吸入
  • 注射
    • 靜脈注射
    • 皮下
  • 口服

第10章：依患者特徵分類的支氣管擴張治療市場

  • 成人版
  • 老頭
  • 孩子們

第11章 按支氣管擴張類型分類的支氣管擴張治療市場

  • 圓柱形（管狀）
  • 隆起的（囊性）

第12章 支氣管擴張藥物市場（依分銷管道分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 各地區支氣管擴張藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 支氣管擴張藥物市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國支氣管擴張藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • AdvaCare Pharma
    • Armata Pharmaceuticals
    • AstraZeneca PLC
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Cipla Limited
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline PLC
    • Glenmark Pharmaceuticals Limited
    • Insmed Incorporated
    • Lupin Limited
    • Merck & Co., Inc.
    • Mylan Inc. by Viatris Inc.
    • Nephron Pharmaceuticals Corporation
    • Novartis AG
    • Perrigo Company PLC
    • Pfizer Inc.
    • Renovion, Inc.
    • Sanofi SA
    • Steris Healthcare Pvt. Ltd.
    • Sun Pharmaceutical Industries Limited
    • Teva Pharmaceutical Industries Ltd.
    • Verona Pharma PLC
    • ZAMBON COMPANY SPA
    • Zydus Group
Product Code: MRR-B1685377A3D9

The Bronchiectasis Drugs Market is projected to grow by USD 3.13 billion at a CAGR of 9.46% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.52 billion
Estimated Year [2025] USD 1.65 billion
Forecast Year [2032] USD 3.13 billion
CAGR (%) 9.46%

A concise and authoritative orientation to bronchiectasis pharmacotherapy developments, clinical priorities, and the evolving framework for therapeutic innovation

Bronchiectasis has emerged from clinical obscurity to become a focal point for drug development, driven by improved diagnostic recognition, expanding therapeutic hypotheses, and a growing emphasis on quality-of-life outcomes. Recent years have seen a convergence of research efforts across anti-inflammatory strategies, targeted antimicrobial approaches, airway clearance modalities, and symptomatic bronchodilation, all informed by advances in imaging, sputum microbiology, and longitudinal patient registries. This combination of clinical insight and translational science has reshaped how clinicians and industry stakeholders view the disease as a treatable chronic condition rather than an inevitably progressive one.

Consequently, pipelines now reflect a blend of repurposed agents, novel molecular entities, and delivery-optimized formulations intended to address the multifactorial pathophysiology of bronchiectasis. Regulatory dialogues increasingly emphasize patient-reported outcomes and exacerbation reduction as meaningful endpoints, while payers and providers focus on therapies that demonstrably reduce healthcare utilization and improve daily functioning. As a result, strategic decision-making requires an integrated view of clinical evidence, therapeutic differentiation, and practical adoption barriers to translate scientific advances into sustainable patient benefit.

An incisive account of how targeted immunomodulation, therapeutic personalization, and delivery innovation are reshaping treatment paradigms for bronchiectasis

The therapeutic landscape for bronchiectasis is undergoing transformative shifts driven by targeted immunomodulation, precision antimicrobial stewardship, and innovations in inhalation delivery systems. First, the emergence of anti-inflammatory strategies that extend beyond broad corticosteroid use-incorporating selective pathway modulators and adjunctive agents-has reframed treatment paradigms to prioritize chronic inflammation control without unacceptable systemic exposure. This shift is coupled with a more nuanced appreciation of airway microbiome dynamics, prompting development of antibiotics and biologics that aim to reduce pathogenic burden while preserving microbial ecology.

Concurrently, device- and formulation-driven advances have reduced the friction of long-term therapy, with inhaled formulations and optimized nebulizer technologies enabling higher local drug concentrations and improved tolerability. On the regulatory and evidence front, stakeholders now place greater weight on patient-centered endpoints, including exacerbation frequency, functional capacity, and health-related quality of life, which in turn influences trial design and postmarketing value demonstration. Taken together, these shifts are fostering a more patient-centric, precision-oriented approach to bronchiectasis management that aligns clinical objectives with product innovation and adoption pathways.

A pragmatic exploration of how recent United States tariff dynamics are prompting supply chain resilience, sourcing adjustments, and procurement strategy shifts in respiratory therapeutics

Recent tariff developments in the United States have introduced a new variable into cross-border supply chains and procurement planning for respiratory pharmaceuticals. While tariffs are applied unevenly across product classes and raw material categories, they can influence sourcing decisions for active pharmaceutical ingredients, excipients, finished dosage forms, and specialized delivery devices. In practice, manufacturers and distributors are reassessing supplier diversification, client contractual terms, and landed-cost models to maintain supply continuity and predictable commercial terms.

In response to tariff-induced cost pressure, several industry participants have either accelerated localization of manufacturing capacity, negotiated longer-term supply contracts with hedging provisions, or optimized product portfolios to prioritize formulations and packaging formats that are less exposed to incremental duties. Buyers and health systems, in turn, are revisiting tender structures and inventory strategies to mitigate short-term price volatility. Crucially, these operational adjustments emphasize resilience: supply chain visibility, alternative sourcing, and collaborative planning with logistics partners help ensure that patient access and therapeutic continuity remain intact despite tariff-related headwinds.

A comprehensive segmentation framework linking therapeutic class, administration route, patient cohorts, disease morphology, and distribution channels to strategic decision-making

A refined segmentation lens clarifies therapeutic and commercial strategies across the bronchiectasis landscape by aligning drug attributes, patient needs, and distribution pathways. When classifying by drug type, anti-inflammatory agents-including corticosteroids and nonsteroidal anti-inflammatory agents-address the chronic inflammatory milieu, while antibiotics concentrate on pathogen suppression and infection control; bronchodilators are differentiated into long-acting and short-acting agents to meet both maintenance and rescue needs, and mucolytics target sputum viscosity and clearance mechanics. This pharmacologic taxonomy informs product positioning, formulary discussions, and combination regimens.

Route of administration drives adherence and delivery considerations: inhalation approaches minimize systemic exposure and support home-based therapy, injection routes-comprising both intravenous and subcutaneous options-are reserved for severe exacerbations or biologic therapies, and oral therapies remain central for ease of use and outpatient management. Patient demographics further nuance clinical strategy, as adult, geriatric, and pediatric populations present differing comorbidity profiles, tolerability windows, and dosing requirements. Disease subtype stratification between cylindrical (tubular) and varicose (cystic) bronchiectasis contributes diagnostic and prognostic context that can influence therapeutic choice and trial cohort selection. Finally, distribution channel segmentation across hospital pharmacies, online pharmacies, and retail pharmacies defines access touchpoints, reimbursement workflows, and patient support program design, all of which are essential for achieving meaningful uptake and sustained adherence.

A strategic regional perspective on how healthcare systems, regulatory frameworks, and delivery ecosystems shape bronchiectasis therapy access and adoption across global markets

Geographic contours shape clinical access, regulatory expectations, and commercialization approaches for bronchiectasis therapies. In the Americas, healthcare systems demonstrate a mix of centralized hospital-led care and expanding outpatient services, with strong emphasis on real-world evidence generation and multi-stakeholder payer engagements. Clinical networks and patient registries in this region support longitudinal outcome tracking and pragmatic studies that inform reimbursement dossiers and guideline development.

Across Europe, Middle East & Africa, regulatory harmonization efforts and diverse reimbursement environments necessitate adaptable clinical narratives and localized health economic arguments. In several jurisdictions, accelerated pathways for unmet-need respiratory therapies coexist with rigorous cost-effectiveness evaluation, requiring tailored evidence packages. In the Asia-Pacific region, heterogeneity in healthcare infrastructure, rapid adoption of inhalation technologies, and growing investment in local manufacturing capacity drive distinct commercialization strategies; partnerships with regional distributors and attention to cold-chain and logistics considerations can materially affect availability and uptake. Taken together, these regional differences underline the importance of flexible market entry plans and evidence generation strategies that reflect local payer priorities and clinical practice patterns.

An informed analysis of competitive positioning, innovation pathways, and collaborative models that define leading companies in the bronchiectasis therapeutics ecosystem

Competitive dynamics in bronchiectasis therapeutics reflect a mix of established respiratory specialists, specialty biotech firms, and larger diversified pharmaceutical companies. Key players often differentiate through proprietary delivery platforms, biologic modalities, or antimicrobial stewardship strategies that reduce resistance risk. Some organizations prioritize incremental innovation by reformulating known active molecules into inhaled or longer-acting forms, thereby improving tolerability and adherence, while others pursue first-in-class targets that modulate specific inflammatory pathways implicated in mucus hypersecretion and airway remodeling.

Collaboration is increasingly prominent, as clinical development often requires access to specialized registries, diagnostic capabilities, and patient support services. Partnerships between developers and contract manufacturing organizations enable flexible scale-up and localized production, and licensing agreements are used to accelerate geographic expansion. From a commercial perspective, market entrants that combine strong clinical differentiation with robust patient support and healthcare professional education programs are better positioned to secure formulary placement and clinical adoption. Moreover, organizations that invest in post-authorization evidence generation and digital adherence solutions tend to strengthen their long-term value propositions.

Practical, high-impact recommendations for leadership teams to accelerate clinical adoption, enhance resilience, and deliver measurable patient benefit in bronchiectasis care

For industry leaders seeking durable differentiation and patient impact, a set of pragmatic actions can accelerate clinical adoption and commercial success. First, prioritize evidence generation that directly addresses payer and clinician concerns: invest in trials and real-world studies that measure exacerbation burden, functional outcomes, and healthcare resource utilization, and complement clinical endpoints with robust patient-reported measures. Second, optimize delivery modalities to lower treatment burden; inhaled and user-friendly formulations that reduce systemic exposure will align with both clinician preference and patient adherence.

Next, strengthen supply chain resilience through supplier diversification, regional manufacturing partnerships, and inventory strategies that reduce vulnerability to tariff and logistics disruptions. Additionally, design distribution and patient support pathways that integrate hospital, retail, and digital pharmacy channels to maximize accessibility and continuity of care. Finally, invest in cross-functional stakeholder engagement-clinical champions, payer evidence teams, and patient advocacy groups-to create aligned value narratives that expedite inclusion in treatment protocols and formularies. These coordinated steps enhance the likelihood that therapeutic innovations translate into improved outcomes and sustained clinical uptake.

A transparent explanation of the mixed-methods research approach blending clinical evidence review, regulatory analysis, stakeholder interviews, and product lifecycle assessment

This research synthesis is grounded in a mixed-methods approach that combines clinical literature appraisal, regulatory landscape review, stakeholder interviews, and synthesis of device and formulation trends. Clinical literature was evaluated with attention to trial design elements, endpoint selection, and safety profiles across therapeutic classes. Regulatory guidance and public filings were examined to identify evolving approval criteria and postmarketing evidence expectations. Primary qualitative inputs from clinicians, formulary managers, and supply chain specialists informed interpretation of adoption barriers and operational constraints.

Complementing qualitative inputs, product and technology assessments focused on delivery systems, manufacturing dependencies, and cold-chain or handling requirements. Cross-validation techniques were used to reconcile disparate data points and ensure consistency of conclusions. Where applicable, sensitivity to regional regulatory and reimbursement variance was applied to refine strategic implications. This blended methodology provides a robust foundation for the insights and recommendations presented, emphasizing practical applicability for clinical development, commercialization, and operations teams.

A conclusive synthesis underscoring the need for integrated clinical, operational, and commercial strategies to realize therapeutic value in bronchiectasis care

Sustaining momentum in bronchiectasis therapeutics requires integrated strategies that bridge scientific innovation, operational resilience, and stakeholder alignment. The evolving evidence base supports a transition toward therapies that are both clinically differentiated and user-friendly, while commercial success will hinge on adaptable distribution models, compelling payer narratives, and demonstrable improvements in patient-centered outcomes. Equally important is the ability to navigate supply chain volatility, regulatory diversity, and shifting clinical expectations with proactive planning and partnership.

Ultimately, the most effective programs will align therapeutic design with real-world use, coupling clinical efficacy with mechanisms to support adherence, access, and long-term value demonstration. Organizations that embrace this holistic view-investing in targeted evidence, resilient operations, and sustained stakeholder engagement-will be best positioned to convert scientific advances into meaningful improvement in patient care and health system performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Efficacy and safety outcomes of inhaled liposomal antibiotics in bronchiectasis management
  • 5.2. Utilization of CFTR modulators repurposed for non-cystic fibrosis bronchiectasis therapy
  • 5.3. Development of monoclonal antibody treatments targeting neutrophilic inflammation pathways in bronchiectasis
  • 5.4. Emerging small molecule biofilm dispersal agents to enhance antibiotic activity in bronchiectasis patients
  • 5.5. Integration of biomarker-driven patient stratification models for personalized bronchiectasis drug therapy
  • 5.6. Impact of real-world evidence studies on long-term outcomes and payer reimbursement in bronchiectasis
  • 5.7. Regulatory incentives and orphan drug designations accelerating novel bronchiectasis treatment approvals
  • 5.8. Challenges of antimicrobial resistance and stewardship in designing next-generation bronchiectasis antibiotics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bronchiectasis Drugs Market, by Drug Type

  • 8.1. Anti-Inflammatory Agents
    • 8.1.1. Corticosteroids
    • 8.1.2. NSAIDs
  • 8.2. Antibiotics
  • 8.3. Bronchodilators
    • 8.3.1. Long-Acting Bronchodilators
    • 8.3.2. Short-Acting Bronchodilators
  • 8.4. Mucolytics

9. Bronchiectasis Drugs Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Injection
    • 9.2.1. Intravenous
    • 9.2.2. Subcutaneous
  • 9.3. Oral

10. Bronchiectasis Drugs Market, by Patient Demographics

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Bronchiectasis Drugs Market, by Bronchiectasis Type

  • 11.1. Cylindrical (Tubular)
  • 11.2. Varicose (Cystic)

12. Bronchiectasis Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Bronchiectasis Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Bronchiectasis Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Bronchiectasis Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AdvaCare Pharma
    • 16.3.2. Armata Pharmaceuticals
    • 16.3.3. AstraZeneca PLC
    • 16.3.4. Bayer AG
    • 16.3.5. Boehringer Ingelheim International GmbH
    • 16.3.6. Cipla Limited
    • 16.3.7. F. Hoffmann-La Roche AG
    • 16.3.8. GlaxoSmithKline PLC
    • 16.3.9. Glenmark Pharmaceuticals Limited
    • 16.3.10. Insmed Incorporated
    • 16.3.11. Lupin Limited
    • 16.3.12. Merck & Co., Inc.
    • 16.3.13. Mylan Inc. by Viatris Inc.
    • 16.3.14. Nephron Pharmaceuticals Corporation
    • 16.3.15. Novartis AG
    • 16.3.16. Perrigo Company PLC
    • 16.3.17. Pfizer Inc.
    • 16.3.18. Renovion, Inc.
    • 16.3.19. Sanofi S.A.
    • 16.3.20. Steris Healthcare Pvt. Ltd.
    • 16.3.21. Sun Pharmaceutical Industries Limited
    • 16.3.22. Teva Pharmaceutical Industries Ltd.
    • 16.3.23. Verona Pharma PLC
    • 16.3.24. ZAMBON COMPANY S.P.A.
    • 16.3.25. Zydus Group

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRONCHIECTASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BRONCHIECTASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BRONCHIECTASIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY NSAIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY NSAIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY LONG-ACTING BRONCHODILATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY LONG-ACTING BRONCHODILATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY LONG-ACTING BRONCHODILATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY LONG-ACTING BRONCHODILATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY LONG-ACTING BRONCHODILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY LONG-ACTING BRONCHODILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SHORT-ACTING BRONCHODILATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SHORT-ACTING BRONCHODILATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SHORT-ACTING BRONCHODILATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SHORT-ACTING BRONCHODILATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SHORT-ACTING BRONCHODILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SHORT-ACTING BRONCHODILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CYLINDRICAL (TUBULAR), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CYLINDRICAL (TUBULAR), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CYLINDRICAL (TUBULAR), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CYLINDRICAL (TUBULAR), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CYLINDRICAL (TUBULAR), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CYLINDRICAL (TUBULAR), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY VARICOSE (CYSTIC), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY VARICOSE (CYSTIC), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY VARICOSE (CYSTIC), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY VARICOSE (CYSTIC), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY VARICOSE (CYSTIC), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY VARICOSE (CYSTIC), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 307. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 308. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 309. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 318. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 319. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2024 (USD MILLION)
  • TABLE 320. GCC BRONCHIECTASIS DRUGS MARKET SIZE, B